Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

BACKGROUND: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauwels, Kim, Huys, Isabelle, Casteels, Minne, Larsson, Kristina, Voltz, Caroline, Penttila, Karri, Morel, Thomas, Simoens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314481/
https://www.ncbi.nlm.nih.gov/pubmed/28209180
http://dx.doi.org/10.1186/s13023-017-0578-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314481/
https://www.ncbi.nlm.nih.gov/pubmed/28209180
http://dx.doi.org/10.1186/s13023-017-0578-4

Ejemplares similares